Alfred D. Kingsley - Aug 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Director
Signature
/s/ Alfred D. Kingsley
Stock symbol
OCX
Transactions as of
Aug 15, 2022
Transactions value $
$9,700
Form type
4
Date filed
8/17/2022, 08:20 PM
Previous filing
Jul 6, 2022
Next filing
Dec 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Award $0 +10K +2.54% $0.00 404K Aug 15, 2022 Direct F1
transaction OCX Common Stock, no par value Purchase $4.85K +5K +1.24% $0.97 409K Aug 15, 2022 Direct
transaction OCX Common Stock, no par value Purchase $4.85K +5K +1.22% $0.97 414K Aug 15, 2022 Direct
holding OCX Common Stock, no par value 75.3K Aug 15, 2022 See footnote F2
holding OCX Common Stock, no par value 18.8K Aug 15, 2022 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +45K $0.00 45K Aug 15, 2022 Common Stock 45K $0.97 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
F2 The shares of common stock are held by Greenbelt Corp. The Reporting Person is the President of Greenbelt Corp. and in such capacity has the right to vote and dispose of the securities held by such entity.
F3 The shares of common stock are held by Greenway Partners, LP. The Reporting Person is the General Partner of Greenway Partners, LP and in such capacity has the right to vote and dispose of the securities held by such entity.
F4 Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.